Sign Out
Alcohol: Precaution is recommended with concurrent intake of alcohol (see Interaction).
Risk of urinary retention: Caution should be taken in patients with predisposing factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as Levocetirizine may increase the risk of urinary retention.
Risk of seizure aggravation: Caution should be taken in patients with epilepsy and patients at risk of convulsion as Levocetirizine may cause seizure aggravation.
Allergy skin tests: Response to allergy skin tests are inhibited by antihistamines and a wash out period (of 3 days) is required before performing them.
Excipients: Lactose: This product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Withdrawal syndrome: Pruritus may occur when Levocetirizine is stopped even if those symptoms were not present before treatment initiation. The symptoms may resolve spontaneously. In some cases, the symptoms may be intense and may require treatment to be restarted. The symptoms should be resolved when the treatment is started.
Use in Children: The use of the film coated tablet formulation is not recommended in children aged less than 6 years since this formulation does not allow for appropriate dose adaptation. It is recommended to use a pediatric formulation of Levocetirizine.
